Vectura Group (LON:VEC) has received a consensus rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is GBX 142.14 ($2.00).
A number of brokerages recently weighed in on VEC. Peel Hunt reaffirmed a “hold” rating and issued a GBX 160 ($2.25) target price on shares of Vectura Group in a research note on Thursday, February 1st. Shore Capital reaffirmed a “buy” rating on shares of Vectura Group in a research note on Thursday, January 4th. Numis Securities restated a “buy” rating and set a GBX 170 ($2.39) price objective on shares of Vectura Group in a research note on Thursday, January 4th. Citigroup restated a “buy” rating and set a GBX 155 ($2.18) price objective on shares of Vectura Group in a research note on Tuesday, March 20th. Finally, Royal Bank of Canada upgraded shares of Vectura Group to a “sector performer” rating and set a GBX 119 ($1.67) price objective for the company in a research note on Thursday, December 14th.
Shares of LON VEC opened at GBX 81.05 ($1.14) on Wednesday. Vectura Group has a 1-year low of GBX 70 ($0.98) and a 1-year high of GBX 166.97 ($2.34).
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://weekherald.com/2018/04/16/brokerages-set-vectura-group-vec-pt-at-142-14.html.
Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.